ContRoVeRSY And ConSenSuS Meeting Viewpoint Workshop Report for Cancer Research : defining the Shades of Gy : utilizing the Biological Consequences of Radiotherapy in the development of new treatment Approaches

www.aacrjournals.org 1Radiation Research Program, National Cancer Institute, Bethesda, Maryland. 2Radiation Oncology Branch, Centre for Cancer Research, National Cancer Institute, Bethesda, Maryland. 3Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana. 4Department of Epidemiology, University of Maryland School of Medicine, Baltimore, Maryland. 5Radiation Physics Division, NIST, Gaithersburg, Maryland. 6Medical Research Council, Harwell, Didcot, United Kingdom. 7Division of Radiation Oncology, Department of Radiation Physics, The University of Texas, MD Anderson Cancer Centre, Houston, Texas. 8Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, United Kingdom. 9Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. 10Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, Canada. 11Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California. 12Development Therapeutics Program, National Cancer Institute, Bethesda, Maryland. 13Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina. 14Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 15Department of Radiation Oncology, Weill Cornell Medical College, New York City, New York. 16Department of Radiation Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts. 17Department of Radiation Oncology; University of Colorado Cancer Center, Aurora, Colorado. 18Radiation Biology Branch, National Cancer Institute, Bethesda, Maryland.

[1]  C. N. Coleman,et al.  Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example , 2017, Molecular Cancer Therapeutics.

[2]  R. Timmerman,et al.  Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer. , 2017, The British journal of radiology.

[3]  John Humm,et al.  Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma. , 2016, International journal of radiation oncology, biology, physics.

[4]  C. N. Coleman,et al.  Differential Expression of Stress and Immune Response Pathway Transcripts and miRNAs in Normal Human Endothelial Cells Subjected to Fractionated or Single-Dose Radiation , 2014, Molecular Cancer Research.

[5]  Sarah L Kerns,et al.  Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy. , 2014, Cancer discovery.

[6]  J. Brown,et al.  Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy. , 2014, The British journal of radiology.

[7]  A. Fornace,et al.  Long-Term Differential Changes in Mouse Intestinal Metabolomics after γ and Heavy Ion Radiation Exposure , 2014, PloS one.

[8]  C. N. Coleman,et al.  Fractionated Radiation Alters Oncomir and Tumor Suppressor miRNAs in Human Prostate Cancer Cells , 2012, Radiation research.

[9]  Albert J Fornace,et al.  Radiation Metabolomics. 1. Identification of Minimally Invasive Urine Biomarkers for Gamma-Radiation Exposure in Mice , 2008, Radiation research.